[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?",
    "summary": "Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=6f5c41fdcc4add6733bf59447b87fd0692382272073af095b9074d622f6a6fe1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740155425,
      "headline": "Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?",
      "id": 132902117,
      "image": "https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=6f5c41fdcc4add6733bf59447b87fd0692382272073af095b9074d622f6a6fe1"
    }
  },
  {
    "ts": null,
    "headline": "American Century Value Fund Q4 2024 Commentary",
    "summary": "U.S. equities broadly advanced during the quarter, despite a pullback in December. Read more here.",
    "url": "https://finnhub.io/api/news?id=756196ec206fb09c24a05cc1b0af5659728fe6ed931e438d4e57b12c8390790e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740150660,
      "headline": "American Century Value Fund Q4 2024 Commentary",
      "id": 132829730,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "U.S. equities broadly advanced during the quarter, despite a pullback in December. Read more here.",
      "url": "https://finnhub.io/api/news?id=756196ec206fb09c24a05cc1b0af5659728fe6ed931e438d4e57b12c8390790e"
    }
  },
  {
    "ts": null,
    "headline": "Is Johnson & Johnson (JNJ) the Best Non-Tech Stock to Buy Now for Long Term?",
    "summary": "We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other non-tech stocks. Investing in non-technology stocks offers a range of benefits that can enhance an investor’s portfolio, providing diversification, […]",
    "url": "https://finnhub.io/api/news?id=85cc871f784b07b5e7138bc02e9644058919889c5e00a646ceac46070d4c010d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740142363,
      "headline": "Is Johnson & Johnson (JNJ) the Best Non-Tech Stock to Buy Now for Long Term?",
      "id": 132902119,
      "image": "https://s.yimg.com/ny/api/res/1.2/DBFyZ0OZ_JyFkP8R8eQoiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other non-tech stocks. Investing in non-technology stocks offers a range of benefits that can enhance an investor’s portfolio, providing diversification, […]",
      "url": "https://finnhub.io/api/news?id=85cc871f784b07b5e7138bc02e9644058919889c5e00a646ceac46070d4c010d"
    }
  },
  {
    "ts": null,
    "headline": "TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis",
    "summary": "Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patientsThe only SC induction data for an IL-23 inhibitor show statistically significant and...",
    "url": "https://finnhub.io/api/news?id=30c1225a81461a62abf6dcba74548bc5fc822bd070a7b047b127c76f0238eb01",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740121267,
      "headline": "TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis",
      "id": 132827152,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patientsThe only SC induction data for an IL-23 inhibitor show statistically significant and...",
      "url": "https://finnhub.io/api/news?id=30c1225a81461a62abf6dcba74548bc5fc822bd070a7b047b127c76f0238eb01"
    }
  },
  {
    "ts": null,
    "headline": "Allspring Growth Fund Q4 2024 Commentary",
    "summary": "The Allspring Growth Fund underperformed the Russell 3000 Growth Index during the quarter that ended December 31, 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=ae5da5525ce79842b6b62f9e241de2b6e22aca640fbefe60c112d5b625075b6a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740116700,
      "headline": "Allspring Growth Fund Q4 2024 Commentary",
      "id": 132826875,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194656946/image_2194656946.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Allspring Growth Fund underperformed the Russell 3000 Growth Index during the quarter that ended December 31, 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=ae5da5525ce79842b6b62f9e241de2b6e22aca640fbefe60c112d5b625075b6a"
    }
  }
]